5-羟色胺2C受体作为精神分裂症治疗靶点的研究进展
Progress in 5-HT2C receptor as a therapeutic target for treatment of schizophrenia

随着第2代抗精神病药物引起体质量增加和心血管不良反应的报道越来越多，研究者近年来开始将关注点投向治疗精神分裂的新靶点——5-羟色胺2C受体（5-HT2C受体）。一方面，有研究表明激动5-HT2C受体具有降低黑质纹状体多巴胺的作用，推测其潜在的抗精神病作用；另一方面，第2代抗精神病药物对5-HT2C受体的拮抗作用是其引起患者体质量增加的重要因素，反之激动5-HT2C受体则可能具有降低体质量的效应。该文以文献综述的形式就5-HT2C受体的抗精神病效应和与之相关的体质量增加不良反应进行阐述。
：With an increasing number of reports on side effects including antipsychotic induced weight gain and cardiovascular risks, interest of the researchers has been transferred to a new target for the treatment of schizophrenia—serotonin 2C receptor (5-HT2C receptor). On one hand, activation on 5-HT2C receptors can lead to decrease of dopamine in the nigrostriatum, which presents its potential antipsychotic effect; on the other hand, the second-generation of antipsychotics’ antagonism on the 5-HT2C receptors is an important factor of patients weight gain. Conversely, agonism on the 5-HT2C receptors may result in weight loss efficacy. This paper introduced the potential therapeutical effect of 5-HT2C receptor on schizophrenia and the relation between the receptor and correlated weight gain